Restasis (cyclosporine ophthalmic emulsion) is a prescription drug that’s used to treat dry eye syndrome. The drug comes as an emulsion (oily liquid). You usually apply 1 drop into each affected eye ...

Restasis (cyclosporine) is a prescription drug that’s used to treat chronic (long-term) dry eye. Restasis comes as an eye drop. For treating chronic dry eye, doctors may prescribe Restasis for adults ...

You may qualify for free Restasis through the drug’s manufacturer, myAbbVie Assist. That said, you won’t use your Medicare coverage. Restasis (cyclosporine), a brand-name eye drop for chronic dry eyes ...

Yes, people with Medicare Part D who use Restasis may be eligible for a patient assistance program called myAbbVie Assist. This article discusses whether Medicare covers Restasis, Medicare ...

PITTSBURGH, Feb. 3, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received approval from the U.S. Food and Drug Administration ...

Americans who are boosted are 95 times less likely than unvaccinated people to die of COVID-19, the FDA approved the first generic drug for Restasis to treat dry eye syndrome, and CMS is putting a ...

Viatris VTRS announced that the FDA has approved the abbreviated new drug application filed by Mylan Pharmaceuticals, a subsidiary of Viatris, which sought approval for a generic version of Restasis ...